Eli Lilly enters into strategic partnership on metabolic diseases with Regor Therapeutics

Novo Nordisk competitor Eli Lilly has announced a collaboration with Regor Therapeutics within metabolic diseases such as diabetes and obesity.
Photo: Vincent Kessler/Reuters/Ritzau Scanpix
Photo: Vincent Kessler/Reuters/Ritzau Scanpix
by andreas lønstrup, translated by catherine brett

US-based Eli Lilly and Regor Therapeutics Group have entered into a development collaboration and licensing agreement to discover, develop and commercialize new therapies within metabolic diseases like diabetes and obesity.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading